10/581619

AP3 Rec'd PCT/PTO 05 JUN 2000 PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q95329

Kazuyuki OHMOTO, et al.

Appln. No.: Based on PCT/JP04/017961

•

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: June 5, 2006

Examiner: Unknown

For:

BLOOD FLOW PROMOTERS FOR CAUDA EQUINA TISSUES

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

Copies of the listed documents are not presently at hand but should be received from the International Bureau. We will endeavor to supply them upon receipt from Applicants as well.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: Based on PCT/JP04/017961

Attorney Docket No.: Q95329

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

foreign language documents, Applicant encloses herewith a copy of a Communication from a

foreign patent office in a counterpart application citing such documents (International Search

Report for PCT/JP04/017961 dated February 1, 2005), together with an English-language

version (if not already included) of at least that portion of the Communication indicating the

degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 32,197

Mark Boland

lack Boland

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: June 5, 2006

2

10/201017 AP3 Rec'd PCT/PTO 0 5 JUN 2825 A & B (08-03)

	ute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Complete if Known			
Substitute for Form 1449 A & B/PTO		Application Number	Based on PCT/JP04/017961		
INFORMATION DIS	CLOSHDE	Confirmation Number	Unknown		
		Filing Date	June 5, 2006		
STATEMENT BY AP	PLICANI	First Named Inventor	Kazuyuki OHMOTO		
(use as many sheets as r	ecessary)	Art Unit	Unknown		
· ·		Examiner Name	Unknown		
Sheet 1	of 1	Attorney Docket Number	O95329		

U.S. PATENT DOCUMENTS						
Document Number		Publication Date				
	Cite No. ¹	Number	Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		US				
		US				
		US				
		US				
		US				

FOREIGN PATENT DOCUMENTS							
Examiner Cite Initials* No.1	Foreign Patent Document			Publication Date	Name of Patentee or		
	Country Code ³	Number⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶	
		JP	11-130678	Α	05-18-1999	Kaken Pharmaceutical Co., Ltd.	
		wo	03/009872	A1	02-06-2003	ONO PHARMACEUTICAL CO., LTD.	
		wo	03/074483	A1	09-12-2003	ONO PHARMACEUTICAL CO., LTD.	
		EP	0 156 611	A2	10-02-1985	ONO PHARMACEUTICAL CO., LTD.	
		wo	2004/065365	A1	08-05-2004	ONO PHARMACEUTICAL CO., LTD.	
		-			-		

NON PATENT LITERATURE DOCUMENTS					
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			
		Y. LIU, "Rat Umao Shinkei Appaku Hoko Shogai Model Deno Beraprost Natrium to Limaprostal fadex Tono Hikaku", Basic Pharmacology & Therapeutics, 2002 pp. 875-880, Vol. 30, No. 10			
		M. KIRIYAMA, "Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells", 1997, pp. 217-224, Vol. 122, No. 2			
		H. KUWADA, "Effects of prostaglandin derivatives on changes of gastric mucosal protein contents in ethanol-induced ulcer", Cyto-protection & Biology, 1985, pp. 217-225, Vol. 3			
1		KIYOHIRO TSUTSUI, "Procylin Naifuku Toya go Soki Shita Livedo Kekkan'en no 1 Rei", The Journal of Medicine, 1994, pp. 611-613, Vol. 32, No. 3			
		International Search Report for PCT/JP04/017961			
			<u> </u>		

Examiner Signature	 Date Considered	

[Page 1 of 1]

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.